GW Pharmaceuticals Continues to See Positive Results from Epidiolex

Photo Credit: Getty

Photo Credit: Getty

GW Pharmaceuticals began their exploration of Epidiolex, a CBD-based medicine, on symptoms of two treatment resistant forms of epilepsy back in early 2016. They have now recently published the results of their third phase of the study, and study author Elizabeth Thiele, M.D., Ph.D., says, "For many children with treatment-resistant Dravet Syndome, Lennox-Gastaut syndrome, and other epilepsies, CBD appears to be an effective - sometimes extremely effective - treatment that is safe and well-tolerated overall."

The controlled study looks at 120 children with Dravet Syndrome for 14 weeks, with 61 receiving Epidiolex twice a day and 59 receiving placebo. Those who received the medication experienced an average decline in seizures per day by an average 39%, with three of the patients eliminating seizures all together, while those who received placebo only experienced a decline in seizures by about 13%. The study also tracked 171 children and adults between the ages of 2 and 55 diagnosed with Lennox-Gastaut Syndrome over the course of 14 weeks. Similarly, the patients were administered their doses twice a day, with 86 receiving Epidolex and 85 receiving placebo. Those who received Epidiolex witnessed a drop in seizures by 44%, with those receiving placebo only witnessing a reducing by 22%. 

This information has been provided by Marijuana Times and approved by our Chief Medical Officer.